In the first month since it filed for Chapter 11 protection, Vermillion suffered a net loss of more than $440,000, according to documents filed with the US Bankruptcy Court in Delaware.

According to the documents filed last week, Vermillion posted a net loss $441,168 in April. As of April 30 it had cash and cash equivalents of $575,568, which included $568,930 in cash.

On March 31, the day after it filed for bankruptcy protection, the company had cash and cash equivalents of $613,917, including $610,214 in cash.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.